International Association for the Study of Lung Cancer | IASLC
Login Donate
NewsContactHelp
Login

IASLC_covid19

 

telehealth

ILCN will be featuring numerous physician and patient perspectives about the challenges and benefits associated with telehealth, as well as discussing the “new normal” imposed by the COVID-19 pandemic regarding shifts in provider education, standards of care, and clinical trials

Read the Article

Lung Cancer Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.

We are seeking volunteers to submit data on thoracic cancer patients diagnosed between January 1, 2011, and December 31, 2019 to a secure, electronic data capture system provided by Cancer Research And Biostatistics (CRAB) in Seattle, Washington.

Be a Part of It



Join Now - Become a Member

Join the only network of specialists working to conquer lung and thoracic cancers worldwide. As a member, you can collaborate with a global team of thoracic oncology experts and gain access to the latest, ground-breaking research in lung cancer prevention, detection and treatment.

Join Now

Journal of Thoracic Oncology

Lung and thoracic specialists count on the IASLC’s Journal of Thoracic Oncology to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal focusing on lung and thoracic cancers, the journal is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community.

Go to the Journal

IASLC News

July 10, 2020
IASLC Statement on Upcoming Events
Due to this evolving situation, including the possibility that travel restrictions and limitations on large gatherings will persist, at this time the IASLC is transitioning its live conferences to virtual conferences through January 2021. 
Read More
June 29, 2020
Journal of Thoracic Oncology Impact Factor Continues to Increase
Journal of Thoracic Oncology Impact Factor Continues to Increase
Read More
May 20, 2020
IASLC Survey: Molecular Testing Rates in Most Countries Less than 50 ...
Access to targeted therapies for lung cancer depends on accurate identification of patients’ biomarkers through molecular testing, but survey results published today in the Journal of Thoracic Oncology suggest that many international clinicians are unaware of evidence-based guidelines that support the use of molecular testing.
Read More




View News Archive

Events

View Event Calendar

Virtual Library

IASLC Publications

From specialized atlases to our award-winning textbook, IASLC publications are an invaluable educational resource for the thoracic oncology community.

View Publications

On Nearly Every Continent, Our Members Are Working Toward a World Without Lung and Thoracic Cancers

Asset 4

At IASLC, Our Mission is

 To Conquer Thoracic Cancers Worldwide